Latest from the Newsroom

November 8, 2016

Last week, global stakeholders convened for the third annual Lausanne Workshop to identify, address and overcome barriers on the road to stopping Alzheimer’s by 2025. Alzheimer’s experts from government, industry, patient advocacy, regulation, public policy and academia learned lessons from those closest to Alzheimer’s disease as well as experts in other disease areas. Their goal was to challenge traditional approaches to care, drug development, regulatory and market access issues.

August 22, 2016

The discussion between industry and payers is critical for establishing a shared approach to the challenges of Alzheimer’s disease both now and in the future. This conversation builds on the multi-stakeholder roundtable at ISPOR on May 23, 2016 in Washington, DC and sets our course towards a global action plan to be established at the annual meeting in Lausanne, Switzerland on October 27-28, 2016.

August 19, 2016

Alzheimer’s disease and related dementias affect nearly 50 million individuals worldwide, with prevalence projected to double over the next twenty years. In that same time period, well over 100 million people will die as a result of this disease, an epidemic larger than any in human history.

August 18, 2016

In this paper, we discuss some of the key challenges of AD drug development that are pertinent to the regulatory environment and highlight regulatory activities that have been and are being put in place to address these challenges.

January 20, 2016

National Launch Engages Major Institutions in Atlanta, Boston, Las Vegas, Providence (Rhode Island), San Francisco and South Florida

TV Stars Linda Gray and Samantha Harris and Renowned Author B. Smith Join Effort

January 14, 2016

Becomes the newest member of a growing coalition to advance innovation in Alzheimer’s disease research

Washington, DC – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that Axovant Sciences will join the CEOi as part of its ongoing effort to advance innovations in drug development and care delivery to stop Alzheimer’s by 2025. 

December 17, 2015

European, North American and Asian leaders from industry, government, science and advocacy convene in Lausanne for critical discussions

October 12, 2015

Becomes the newest member of a growing coalition to advance innovation and solutions in Alzheimer’s

Washington, DC – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that Axovant Sciences will join the CEOi as part of its ongoing effort to advance innovations and solutions in Alzheimer’s drug development and care delivery. 

March 19, 2015

Nice, France -- The Global Alzheimer’s Platform (GAP) and the Innovative Medicines Initiative (IMI) announced today that they will sign a Memorandum of Understanding (MOU) to accelerate Alzheimer’s drug development by building a global, standing, trial-ready platform for Alzheimer’s drug development.  The collaboration represents a significant commitment to work together to recruit patients for clinical trials, to create a high-performing clinical trial system, and to develop a standing adapt

March 17, 2015

Geneva, Switzerland – Following is a statement by George Vradenburg, convener of the Global CEO Initiative (CEOi) on Alzheimer’s Disease, on today’s announcement by UK Health Secretary Jeremy Hunt that more than $100 million has been raised to support the Dementia Discovery Fund.  The fund, which was created by the British government, is unique because it is bringing together government an

Pages